Patent Assignment
Reel/Frame 050750/0497
Change of Name
Recorded: 2019-10-17
Pages: 8
Assignor
NALPROPION PHARMACEUTICALS, INC.
Executed: 2019-09-27
Assignee
NALPROPION PHARMACEUTICALS LLC
10 NORTH PARK PLACE, SUITE 201, MORRISTOWN, NEW JERSEY, 07960
Covered Properties
(35)
Compositions for Affecting Weight Loss
Compositions for Affecting Weight Loss
Compositions and methods for increasing insulin sensitivity
Sustained Release Formulation of Naltrexone
Layered Pharmaceutical Formulations
Methods for Administering Weight Loss Medications
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Layered Pharmaceutical Formulations
Methods for Reducing Binge or Compulsive Eating
Application:
13/991,372 →
Publication:
US 2013/0252995
Methods for Administering Weight Loss Medications
Compositions and Methods for Weight Loss in at Risk Patient Populations
Patent:
8,969,371 →
Application:
14/322,810 →
Compositions and Methods for Increasing Insulin Sensitivity
Methods of Treating Overweight and Obesity
Sustained Release Formulation of Naltrexone
Compositions and Methods for Weight Loss in at Risk Patient Populations
Compositions and Methods for Weight Loss in at Risk Patient Populations
Layered Pharmaceutical Formulations
Application:
14/988,556 →
Publication:
US 2016/0338965
Methods of Providing Weight Loss Therapy in Patients with Major Depression
Compositions and Methods for Reducing Major Adverse Cardiovascular Events
Compositions for Affecting Weight Loss
Compositions and Methods for Reducing Food Cravings
Application:
15/411,585 →
Publication:
US 2017/0312269
Methods for Treating Visceral Fat Conditions
Methods of Treating Overweight and Obesity
Compositions and Methods for Weight Loss in at Risk Patient Populations
Methods For Administering Weight Loss Medications
Sustained Release Formulation Of Naltrexone
Application:
16/284,453 →
Publication:
US 2019/0183883
Method for Treating Obesity
Application:
16/293,198 →
Publication:
US 2019/0262318
Compositions And Methods For Weight Loss In At Risk Patient Populations
Compositions And Methods For Reducing Major Adverse Cardiovascular Events
Compositions For Affecting Weight Loss
Compositions And Methods For Increasing Insulin Sensitivity
Application:
16/378,177 →
Publication:
US 2019/0231852
Methods For Administering Weight Loss Medications
Application:
16/428,069 →
Publication:
US 2019/0282503
Methods Of Providing Weight Loss Therapy In Patients With Major Depression
Increasing Drug Bioavailability In Naltrexone Therapy
Application:
16/534,509 →
Publication:
US 2019/0358222
Methods of Treating Overweight and Obesity
Related Assignments
(21)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 9, 2012
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 029121/0736 →
Assignment of Assignor's Interest
Jun 25, 2013
From: DUNAYEVICH, EDUARDO; MCELROY, SUSAN; LANDBLOOM, RON
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 030710/0299 →
Assignment of Assignor's Interest
Mar 18, 2014
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 032463/0479 →
Assignment of Assignor's Interest
Jul 15, 2014
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 033312/0523 →
Assignment of Assignor's Interest
Oct 15, 2014
From: KLASSEN, PRESTON; TAYLOR, KRISTIN
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 033953/0347 →
Assignment of Assignor's Interest
Dec 18, 2015
From: DUNAYEVICH, EDUARDO; DEWITT (LEGAL REPRESENTATIVE OF GARY TOLLEFSON (DECEASED)), DAVID
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 037334/0490 →
Security Agreement
Mar 21, 2016
From: OREXIGEN THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 038180/0021 →
Assignment of Assignor's Interest
Aug 4, 2016
From: MCKINNEY, ANTHONY; TOLLEFSON, GARY; WEBER, ECKARD; SOLTERO, RICK
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 039347/0977 →
Assignment of Assignor's Interest
Mar 20, 2017
From: KLASSEN, PRESTON; TAYLOR, KRISTIN
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041648/0257 →
Assignment of Assignor's Interest
Mar 22, 2017
From: MCKINNEY, ANTHONY A.; TOLLEFSON, GARY D.; SOLTERO, RICHARD; DUNZO, THEA ELISE
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0895 →
Assignment of Assignor's Interest
Mar 22, 2017
From: WEBER, ECKARD; COWLEY, MICHAEL ALEXANDER
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0847 →
Assignment of Assignor's Interest
Mar 22, 2017
From: COWLEY, MICHAEL A; MCKINNEY, ANTHONY A.; TOLLEFSON, GARY
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0886 →
Assignment of Assignor's Interest
Mar 22, 2017
From: DUNAYEVICH, EDUARDO; DEWITT, DAVID
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0920 →
Assignment of Assignor's Interest
Mar 22, 2017
From: KLASSEN, PRESTON; TAYLOR, KRISTIN
To: OREXIGEN THERAPEUTICS, INC.
Reel/Frame 041688/0934 →
Assignment of Assignor's Interest
Aug 2, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 046688/0661 →
Security Interest
Aug 6, 2018
From: NALPROPION PHARMACEUTICALS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 047288/0321 →
Assignment of Assignor's Interest
Sep 20, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 047115/0102 →
Assignment of Assignor's Interest
Oct 24, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 047301/0786 →
Assignment of Assignor's Interest
Oct 24, 2018
From: OREXIGEN THERAPEUTICS, INC.
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 047960/0001 →
Release of Security Interest
Sep 27, 2019
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 050574/0106 →
Security Interest
Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →